Peripheral t cell lymphoma in 2013
This presentation is the property of its rightful owner.
Sponsored Links
1 / 51

Peripheral T-Cell Lymphoma in 2013 PowerPoint PPT Presentation


  • 57 Views
  • Uploaded on
  • Presentation posted in: General

Peripheral T-Cell Lymphoma in 2013. Program Goal. WHO 2008 Classification of Mature T/NK-Cell Neoplasms. Use of the Term PTCL. PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas. International PTCL Study: Major NHL Types by Region.

Download Presentation

Peripheral T-Cell Lymphoma in 2013

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Peripheral T-Cell Lymphoma in 2013


Program Goal


WHO 2008 Classification of Mature T/NK-Cell Neoplasms


Use of the Term PTCL


PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas


International PTCL Study: Major NHL Types by Region


Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL


ALK and ALCL


Outcomes by PTCL Subtypes


Prognostic Indices for PTCL


Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a Prospective Multicenter Study


CHOP: First-line Treatment of PTCL


Alemtuzumab (A) + ChemotherapyFirst-line treatment of PTCL


CHOP+ and Non-CHOP: First-line Treatment of PTCL


Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free Survival of Younger Patients


Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival of Younger Patients (cont)


Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival


Prognostic Factors in Trials of ASCT in First Remission


ICE and Planned ASCT for Relapsed/Refractory T-Cell Lymphoma: PFS From ICE


CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in CR1


Retrospective Analyses of Allogeneic Stem-Cell Transplantation for PTCL


Approved Agents in Relapsed/Refractory PTCL


PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients (n = 111)


Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)


Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL


Brentuximab Vedotin in Relapsed ALCL: Toxicities


Brentuximab: Best Clinical Response by Disease Diagnosis


Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells


Front-line Therapy: Study Design (Combination Therapy Arms)


Front-line Therapy: Best Response by Disease Diagnosis


Bendamustine in T-Cell Lymphoma (BENTLY Trial)


Lenalidomide in Relapsed/Refractory TCL: Phase 2 Trial


Belinostat: PTCL Response Assessed by Central Review


Belinostat: Response Rate by CPRG Lymphoma Diagnosis


Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)


MLN8237: Response (PR + CR) by Histology


IPI-145: A PI3K-δ,γ Inhibitor


Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma


Mogamulizumab (KW-0761)Anti-CCR4 Monoclonal Antibody


Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)


Abbreviations


Abbreviations (cont)


Abbreviations (cont)


Abbreviations (cont)


References


References (cont)


References (cont)


References (cont)


References (cont)


References (cont)


References (cont)


  • Login